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Abstract
Background: Low concentrations of morphine are required for safe dosing for intrathecal injections. Sometimes,
manual dilution of morphine is performed to achieve these low concentrations, but risks dilution errors and
bacterial contamination. The primary goal was to compare the concentrations of morphine and bupivacaine
between four groups of syringes. The secondary goal was to investigate the difference in contamination rate
between these groups.
Methods: Twenty-five experienced anesthesia providers were asked to prepare a mixture of bupivacaine 2.0 mg/ml
and morphine 60 μg/ml using 3 different methods as clean and precise as possible. The fourth method used was
the aspiration of ampoules prepared by the pharmacy. The concentrations of morphine and bupivacaine were
measured by High-Pressure Liquid Chromatography (HPLC). The medication was cultured for bacterial
contamination.
Results: Group 1 (median 60 μg/ml; 95% CI: 59–110 μg/ml) yielded 3 outliers above 180 μg/ml morphine
concentration. Group 2 (76 μg/ml; 95% CI: 72–80 μg/ml) and 3 (69 μg/ml; 95% CI: 66–71 μg/ml) were consistently
higher than the target concentration of 60 μg. The group “pharmacy” was precise and accurate (59 μg/ml; 95% CI:
59–59 μg/ml). Group 2 and “pharmacy” had one contaminated sample with a spore-forming aerobic gram-positive
rod.
Conclusion: Manually diluted morphine is at risk for deviating concentrations, which could lead to increased side-
effects. Medication produced by the hospital pharmacy was highly accurate. Furthermore, even when precautions
are undertaken, contamination of the medication is a serious risk and appeared to be unrelated to the dilution
process.
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Implication statement
This study demonstrates that manual dilution of medica-
tion leads to inaccurate concentrations. This might lead
to unsafe dosing.
Background
Intrathecal administration of morphine is an effective
method of analgesia. A single dose of 100–300 μg pro-
duces analgesia that lasts over 24 h [1, 2]. However, ad-
verse events due to intrathecal morphine, such as late
respiratory depression and pruritus, are described to be
dose dependent [3]. The risk for adverse events may in-
crease in doses > 500 μg [4–6]. Given this narrow thera-
peutic range, accurate dosing is paramount.
To achieve a safe dose of intrathecal morphine, low
concentrations of morphine are necessary. However,
commercially available concentrations of morphine in
the Netherlands range up to 10 mg/ml or 20 mg/ml.
Some health care providers use small volumes of 10 mg/
ml morphine to achieve a dose of 150 μg, others dilute
the morphine manually [7–9]. This leaves room for error
with potentially fatal outcomes as a result.
In addition, precautions should be taken to prevent a
contaminated injection, since the introduction of bac-
teria into the cerebrospinal fluid can lead to meningitis
[10]. Even though the incidence of meningitis after an
intrathecal injection is estimated to be 1:53.000, manipu-
lations for manual dilution could contaminate the injec-
tate and increase this incidence [11].
The objective of the current study is to measure preci-
sion and accuracy in dilution of morphine and bacterial
contamination. Previous studies have investigated the di-
lution of morphine, but limited conclusions can be drawn
due to their study design [8, 9]. The methodology was
non-standardized [8] and a limited number of subjects di-
luted the morphine [9]. This may overestimate the accur-
acy of clinical practice. Moreover, bacterial contamination
was not measured. In this study, various experienced
anesthesia providers prepared the syringes according to
three standardized methods of dilution and syringes ex-
tracted from ampoules prepared by our pharmacy. We hy-
pothesized that the number of manoeuvres increases the
risk for a dilutional error and bacterial contamination.
Methods
For this experimental study, medical ethical approval
was waived by the medical ethical committee of the.
Maasstad Hospital (Toetsingscommissie Wetenschap-
pelijk Onderzoek Rotterdam e.o., February 5, 2018). The
primary outcome was the precision and accuracy in
morphine concentration within groups. The secondary
outcome the difference in contamination rate between
these groups.
Twenty-five experienced anesthesiologists and nurse
anesthetists were asked to prepare a mixture of bupiva-
caine and morphine according to predefined methods.
The characteristics of these methods are described in
Table 1. The target concentrations were 2.0 mg/ml bupi-
vacaine and 60 μg/ml morphine. They were provided
with medication, sterilely packed syringes and needles
and aseptic measures, as written below.
Medication
For this study, commercially available medication was
used for the first three methods. Specifically, bupivacaine
5 mg/ml (5 ml), morphine 1 mg/ml (1 ml) and morphine
10mg/ml (1 ml). For the group Pharmacy, the hospital
pharmacy provided ready-to-use (RTU) ampoules of 5
ml, containing a combined solution of 2.5 mg/ml bupiva-
caine and 60 μg/ml morphine. The ampoules were pre-
pared under Good Manufacturing Practice (GMP)
conditions by the pharmacy that is GMP certified by the
Dutch Health Care Inspectorate. In short, a batch of 50
sterile ampoules were prepared. The solution was pre-
pared in a Grade A with Grade C background aseptic
cleanroom and glass ampoules were filled under nitro-
gen. The fluid was filtered through a 0.22 μm bacterial
filter. The ampoules were sterilized in the autoclave for
15 min in 121 degrees Celsius. Quality control tests in a
GMP accredited laboratory included sterility, fill volume,
shelf-life, and concentration.
Experimental design
The participants received written and oral instructions
for preparation of the syringes. It was stressed that the
mixtures needed to be as clean and precise as possible.
The preparation of medication was performed on the
Post Anesthesia Care Unit, on a clean table, specifically
Table 1 Characteristics of dilution per method
Group Starting concentration Number of dilutions Dilution volume
Method 1 10 mg/ml morphine 1 100ml NaCl 0.9%
Method 2 10 mg/ml morphine 2 9 ml NaCl 0.9%, twice
Method 3 1mg/ml morphine 1 9 ml NaCl 0.9%
Pharmacy 60 mcg/ml morphine
2.5 mg/ml bupivacaine
0 N/A
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used for preparation of medication. As aseptic measures,
caps and blue nitrile gloves, but not facemasks were
worn by the participants. All ampoules were swiped with
70% ethanol before opening. The outside of the am-
poules was not touched by the BD blunt fill needles (BD,
Oxford, United Kingdom). After each diluting step, the
providers were advised to use a new needle.
There were four methods to which a participant was
obliged to prepare a syringe. Method 1 was diluting 10
mg/ml of morphine in a single step. It started with
drawing up 1 ml of 10 mg/ml morphine. This was
injected in a container of 100 ml NaCl 0.9%. Three ml
of this mixture was aspirated into a 5 ml syringe and 2
ml of 5 mg/ml bupivacaine was added. Method 2 was a
double-dilution method from 10 mg/ml of morphine. It
started with drawing up 1 ml of 10 mg/ml morphine in
a 10 ml syringe. This was diluted with 9 ml of NaCl
0.9% in the same syringe. After mixing, 9 ml of this
content was discarded and the remaining 1 ml was di-
luted again with 9 ml of NaCl 0.9%. After mixing, 3 ml
of this mixture was aspirated in a 5 ml syringe and 2 ml
of 5 mg/ml bupivacaine was added. Method 3 was a sin-
gle dilution step of 1 mg/ml morphine. It started with
aspiration of 1 ml of 1 mg/ml morphine into a 10 ml
syringe. This was diluted with 9 ml of NaCl 0.9%. After
mixing, 3 ml of this mixture was aspirated in a 5 ml syr-
inge and 2 ml of 5 mg/ml bupivacaine was added. For
group Pharmacy the aforementioned 5 ml ready-to-use
ampoule of bupivacaine and morphine was aspirated
into a 5 ml syringe.
After each prepared syringe, the participants were ad-
vised to change into new nitrile gloves. Participants
could perform their tasks at their own speed. Two syrin-
ges per method were prepared, leading to a total of 8 sy-
ringes per provider. Syringes were marked after each
preparation. The participants started with method 1 then
method 2 and proceeded to method 3. Pharmacy group
contained syringes drawn from pharmacy prepared am-
poules. Per method, one syringe was analysed for drug
concentration and one for bacterial contamination. No
materials were re-used for method 2, 3 and pharmacy
group. For method 1, two samples were taken from the
same 100 ml 0.9% NaCl-container.
After preparation, all the syringes were capped and
analysed the same day in the pharmacy department for
drug concentrations and bacterial contamination. The
syringes were tested for concentration of morphine and
bupivacaine by High-Pressure Liquid Chromatography
(HPLC) at 285 nm in a 125 mm X 4mm fluid column.
Testing of the microbiological culture was done with the
standardized method of the pharmacy department by
injecting the fluid through a filter and culturing for 7
days of the filter. The contaminating microbes were
identified in positive cultures.
Statistics
A power analysis was performed with GPower 3.1. A
concentration was deemed clinically acceptable if the
concentration was in the range between 48 mcg/ml and
72 mcg/ml of morphine. This would be a target concen-
tration of 80% or 120%, with an assumed standard devi-
ation of 20%. We assumed that the concentration in the
group “Pharmacy” would be a mean of 60 mcg/ml with
a margin of error of 2 mcg/ml, leading to a target con-
centration of 100% with a deviation of 3%. In order to
detect between the groups, using an alpha of 0.05 and a
beta of 0.8, 10 samples per group were necessary. To in-
crease accuracy and correct for multiple testing, 25 sam-
ples per group were obtained.
Data is described as n (%) or as median (95% Confidence
Interval). The Chi-square-test was used for original data.
Kruskal-Wallis was used for the testing of continuous
data. A p < 0.005 was considered appropriate and Bonfer-
roni correction was applied when necessary. All testing
was performed with SPSS 25.0 (IBM, Armonk, New York)
and graphics were made by GraphPad Prism version 7.1
(GraphPad Software, San Diego, California).
Results
All continuous data showed a non-normal distribution
(Shapiro-Wilk-test, p < 0.05). The distribution of the
morphine is displayed in Fig. 1. Details of morphine and
bupivacaine concentrations are presented in Table 2.
Group 1 had three outliers with morphine concentra-
tions of 189, 246 and 287 μg/ml. Morphine concentra-
tions were most precise in the pharmacy group (59 μg/
ml; 95% CI of 59–59 μg/ml) followed by group 3 (69 μg/
ml; 95% CI of 66–71 μg), group 2 (76 μg/ml; 95% CI of
72–80 μg/ml) and finally group 1 (60 μg/ml; 95% CI of
59–110 μg/ml). Groups 2 and 3 reached higher concen-
trations than the pharmacy group (p = 0.000, Fig. 1).
Accuracy was calculated as the difference between the
individual measurements and the target-concentration.
No difference in accuracy between group 2 and 3 was
detected (16 μg (10–22) [2–33] vs. 9 μg (6–15) [1–28],
p = 0.329). The pharmacy group was the most accurate
(p = 0.000 for all comparisons with groups 1, 2 and 3).
No difference in accuracy between groups 1 and 3 was
detected (2 μg (95% CI: 2–51) vs. 9 (95% CI: 7–11 μg),
p = 0.645).
Bupivacaine concentrations were not different between
groups 1–3 (p = 1.000 for all comparisons). Since the
pharmacy group had a higher concentration, we calcu-
lated the difference between the target and the measured
concentrations. Again, no difference was detected (p =
1.000 for all comparisons).
There was no relation detected between the anesthesia
provider and the accuracy of the morphine concentra-
tions (P = 0.462).
Teunissen et al. BMC Anesthesiology          (2020) 20:244 Page 3 of 6
Two samples had positive cultures with spore-forming
aerobic gram-positive rods (group 2 & 4) (p = 1.000).
These were prepared by the same provider. In one sam-
ple a fiber was detected (group 2).
Discussion
Our results show that diluting a medicine manually is
prone to deviating concentrations, even by experienced
personnel. The concentrations in the group “Pharmacy”
were precise and accurate. Of the manual dilution
methods, the 3rd led to most accurate and precise concen-
trations. This means that a lower starting concentration
leads to higher precision and accuracy. Contamination oc-
curred in groups 2 and pharmacy group.
The dilution method in group 1 resulted in three cases
with concentrations which could result in respiratory de-
pression when injected intrathecally. If five millilitres of
these solutions would have been injected it would result
in an injected dose of 1 to 1.5 mg intrathecally, while the
targeted dose is 300 μg. Therefore, this method should
not be used. It illustrates that this dilution process is at
risk of creating dangerously high morphine concentra-
tions. The erroneous high concentration is possibly
achieved because no new extraction needle was used
and by the lack of rinsing off the first extracting needle
in this protocol, thereby leaving a small volume of high
concentration morphine in the needle. A second explan-
ation may be because the solution did not mix properly
in the 100 ml container [9].
The precision of group 2 and 3 was clinically accept-
able, even though the accuracy was limited. When these
methods of dilution are clinically applied, one has to aim
for the lower limit of the therapeutic range of intrathecal
morphine to prevent an inadvertently high dose. The
higher concentration is possibly caused by the excess
volume of a 1.0 ml morphine ampoule, which has to be
more than 1.0 ml to allow an extractable volume of 1.0
ml [12]. We believe that methods 2 and 3 are inherently
Table 2 Details of concentrations of morphine and bupivacaine
Group Method 1 Method 2 Method 3 Pharmacy
Morphine concentration (μg/ml) 60 (59–110) 76 (72–80) 69 (66–71) 59 (59–59)
Bupivacaine (mg/ml) 1.98 (1.73–2.06) 2.00 (1.95–2.03) 1.97 (1.91–2.00) 2.54 (2.54–2.55)
Morphine Out-of-range (< 80%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Morphine Out-of-range (> 120%) 7 (28%) 18 (72%) 3 (12%) 0 (0%)
Bupivacaine
Out-of-Range (< 80%)
1 (4%) 0 (0%) 1 (4%) 0 (0%)
Bupivacaine
Out-of-Range (> 120%)
0 (0%) 1 (4%) 0 (0%) 0 (0%)
Data presented as median (95% CI) or n (%) where appropriate
Fig. 1 Morphine concentrations. Box and whiskers demonstrate the median, interquartile range and range
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safer methods, because the needle is rinsed if no new
needle is used and the solution is mixed by aspiration of
9 ml of saline. This is supported by the study of Benkha-
dra et al., which shows that mixing of the syringe results
in a homogenous distribution of the solution [9]. Even
though this was a relatively minor effect, every cause for
imprecision should be excluded.
Most remarkably, 2 groups contained a contami-
nated sample, despite precautions of clean prepar-
ation, such as wearing non-sterile gloves and caps
and swiping the ampoule with 70% ethanol before
opening. In addition, this study was performed in the
Post Anesthesia Care Unit, a room where intrathecal
injections are commonly performed. We did not in-
struct the participants to wear face masks, because we
prepared the solutions as in daily practice. Dilution
steps did not appear to increase bacterial contamin-
ation. Given the rate of contamination, it is surprising
that the incidence of bacterial meningitis after an
intrathecal injection is around 1: 53.000 [11].
Several pathways for contamination of intrathecal in-
jection are described. One pathway consists of bacteria
originating from the oropharynx of the healthcare pro-
vider falling on the sterile area and instruments. The
aerobic spores are predominantly found on skin and ma-
terials, but seldom in the human oral cavity, making it
unlikely that wearing a face mask during preparation
would change the results. A second pathway is that con-
taminated particles fall in the ampoule when this is
opened [10, 13]. Based on the identified spores, this
pathway is more likely. The current study shows con-
taminated medication could be an important pathway of
introducing a microorganism into the cerebrospinal fluid
and our precautions fail to prevent contamination by
this bacterium [14].
This contamination with aerobe gram-positive rods
is most likely Bacillus cereus which is also part of the
human skin flora and commonly associated with con-
tamination [15]. The spores of Bacillus cereus are
alcohol-resistant [16]. In healthy patients, the possibil-
ity of a Bacillus cereus infection in the central ner-
vous system is low because of intact host resistance.
In immunocompromised patients, however, Bacillus
cereus was identified as causative microorganism for
meningitis leading to fatal outcomes [17, 18]. The in-
ability to remove the spores with alcohol might pose
a risk in immunocompromised patients, even though
a Bacillus cereus-meningitis is rare. It is possible al-
though difficult to remove the spores of Bacillus ce-
reus by using disinfection procedures with solutions
containing high concentration chlorine or hydrogen
peroxide.
Bupivacaine was added to measure control of volume.
This study showed that the aspiration of 2 ml into a 5 ml
syringe is accurate. Furthermore, bupivacaine has anti-
bacterial properties, making it of interest for the meas-
urement of contamination [19]. Despite this antibacterial
effect, contamination occurred in 2% of the syringes.
The difference in bupivacaine concentration between
group pharmacy (2.5 mg/ml) and the other groups (2.0
mg/ml) is unlikely to affect the contamination rate [20,
21].
A few recommendations can be made based on this
study. Firstly, prefabricated drugs should be preferred in
clinical practice. In some countries, dilution of medica-
tion is regarded as compounding of medication and is
subject to strict regulations. If prefabricated medication
is not available, one should dilute from the lowest pos-
sible starting concentration and mix the syringe during
the process.
Secondly, sterile precautions should be undertaken
when medication for intrathecal use is prepared, since
bacterial contamination is likely to occur as shown by
Zacher et al. [13] Several hospitals routinely prepare
drugs with high microbiological risk, such as intrathecal
administrations, in a cleanroom environment, either
centrally in the hospital pharmacy or decentral in a lam-
inar flow cabinet in close proximity to the operation the-
atres. Contamination occurs during dilution or
aspiration of medication. Our study fails to demonstrate
a lower risk of contamination with ready to use (RTU)
medication. Prefilled sterile syringes, which are ready to
administer (RTA) could be an alternative for (RTU)
medication. Use of these prefilled syringes would avoid
drawing up the medication. The effects of using prefilled
sterile syringes on contamination should be investigated
further.
Thirdly, clinical studies regarding intrathecal morphine
sometimes do not describe the manufacturing process
[22] or dilute manually [23]. Manually diluted drugs
could yield a variance in dose with a different effect/side
effect ratio. Therefore, the manufacturing process should
be described in clinical studies.
A limitation of this study is that we did not determine
the species beyond the gram-stain.
Gram positive aerobe spore forming bacteria are either
Bacillus antracis or Bacillus cereus. The first would be
very unlikely. Additionally, the bupivacaine concentra-
tion in the group pharmacy differed from the other
groups, although this range of bupivacaine is unlikely to
affect the contamination rate of Bacillus cereus [21].
Also, the incidence of contamination was not less in the
pharmacy group.
Conclusion
Manual dilution of medication may lead to inaccurate
concentrations. We recommend using prepared solu-
tions from the hospital pharmacy. If these are not
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available, it is advised to use the lowest starting concen-
tration available. In studies, the medication should be
produced by the pharmacy since manual dilution can
cause an erroneous dose. Contamination of medication
is a serious risk and precautions should be taken ser-
iously, even though in this study it appeared to be unre-
lated to the method used.
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